In this issue:
Survival benefit to disitamab vedotin plus immunotherapy in bladder cancer
Durvalumab-BCG improves DFS in resected NMIBC
Neoadjuvant TAR-200 + cetrelimab promising for MIBC
Renal dysfunction does not mitigate efficacy of EV + pembrolizumab in UC
KEYMAKER-U03 substudy: Novel front-line triplets for ccRCC
Ultra-hypofractionated radiotherapy non-inferior for localised prostate cancer
Post-ICI lenvatinib plus everolimus bests cabozantinib for progressive ccRCC
Promising activity for sac-TMT in pre-treated advanced UC
High-dose chemotherapy improves prognosis in multiply relapsed germ cell tumors
Erdafitinib ± cetrelimab for cisplatin-ineligible FGFR-altered UC
Please login below to download this issue (PDF)